Leukemia News and Research

RSS

Leukemia (Leukaemia) is a cancer of the blood cells. It is the most common type of blood cancer and affects 10 times as many adults as children. Most people diagnosed with leukemia are over 50 years old. No one knows why some people develop leukemia and others do not. However, scientists have identified some risk factors for the disease. Most people who have known risk factors do not get leukemia, while many who do get the disease have none of these risk factors. During the early stages of leukemia, there may be no symptoms. Many of the symptoms of leukemia don't become apparent until a large number of normal blood cells are crowded out by leukemia cells.

Gene 'addiction' of leukaemia cells

An international team of scientists studying acute forms of Leukaemia have identified a new drug target to inhibit the genes which are vital for the growth of diseased cells. The research, reported in EMBO Molecular Medicine, reveals how leukaemia cells become 'addicted' to genes, which if targeted could prevent diseased cells from developing.

3 Mar 2010

Synta Pharmaceuticals receives FDA approval for resuming elesclomol clinical development

Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today reported that the U.S. Food and Drug Administration (FDA) has approved resuming clinical development of elesclomol, the Company's first-in-class oxidative stress inducer.

2 Mar 2010

Study results of new PCR technology that reports mutations associated with FXS announced

Asuragen, Inc. announced today the results of a collaborative study with scientists at the M.I.N.D. Institute at the University of California Davis evaluating a new PCR technology that reproducibly reports mutations associated with Fragile X syndrome (FXS).

2 Mar 2010

GTC Biotherapeutics achieves high-level production of TG20 monoclonal antibody

GTC Biotherapeutics, Inc. announced that it has achieved high-level production of TG20; an anti-CD20 monoclonal antibody (MAb). The TG20 MAb, which is produced in the milk of transgenic goats, is being co-developed by GTC and LFB as part of the LFB-GTC joint venture.

2 Mar 2010

ARIAD Pharmaceuticals' investigational pan-BCR-ABL inhibitor receives FDA and EMA orphan drug designation

ARIAD Pharmaceuticals, Inc. today announced that its investigational pan-BCR-ABL inhibitor, AP24534, has been granted orphan drug designation by both the U. S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). In the U.S., the orphan designation of AP24534 is for the treatment of chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) and in the E.U., its orphan designation is for CML and acute lymphoblastic leukemia.

2 Mar 2010

ChemGenex Pharmaceuticals' OMAPRO review: FDA reschedules ODAC meeting to 22 March, 2010

ChemGenex Pharmaceuticals Limited announced today that the U.S. Food and Drug Administration (FDA) has rescheduled the previously postponed Oncologic Drugs Advisory Committee (ODAC) meeting to 22 March 2010.

1 Mar 2010

Aprepitant drug can reduce nausea and vomiting when combined with other anti-nausea drugs

Bone marrow transplant patients say two of the most debilitating side effects of the treatment are nausea and vomiting caused by chemotherapy and radiation.

1 Mar 2010

Researchers find gene regulator that plays key role in DS-AMKL

Between 5 and 10 percent of babies with Down syndrome develop a transient form of leukemia that usually resolves on its own. However, for reasons that haven't been clear, 20 to 30 percent of these babies progress to a more serious leukemia known as Down syndrome acute megakaryoblastic leukemia (DS-AMKL), which affects the blood progenitor cells that form red blood cells and platelets.

1 Mar 2010

MLL cancer cells rely on normal protein to proliferate

Researchers have found that one particularly aggressive type of blood cancer, mixed lineage leukemia (MLL), has an unusual way to keep the molecular motors running. The cancer cells rely on the normal version of an associated protein to stay alive.

27 Feb 2010

Cancer researchers assess PCI-32765 drug that targets molecular abnormalities of lymphoma cells

Cancer researchers have high hopes for a new therapy for patients with certain types of lymphoma and leukemia.

27 Feb 2010

Vion Pharmaceuticals' Onrigin SPA: FDA responds

VION PHARMACEUTICALS, INC. announced today that it had received a response from the U.S. Food and Drug Administration on a Special Protocol Assessment for its oncology therapeutic Onrigin™ (laromustine) Injection.

26 Feb 2010

Fate Therapeutics named to Technology Review's 2010 TR50 most innovative companies in the world list

Fate Therapeutics, Inc. announced today that the Company was named as one of Technology Review's 2010 TR50, the publication's first annual list of the 50 most innovative companies in the world. The 2010 TR50 companies span the fields of energy, computing, the Web, biomedicine, and materials and have been evaluated based on business model, strategies for deploying and scaling up its technologies and the likelihood of success. Each company in the 2010 TR50 has excelled not only at inventing technology but also at using it to transform how we live and work.

26 Feb 2010

Genoptix to participate in Aetna's national provider network to offer laboratory and diagnostic services

Genoptix, Inc. today announced that it will participate in Aetna's (AET) national provider network to offer specialized laboratory and comprehensive diagnostic services designed to optimize the care of patients suffering from hematomalignancies, or cancers of the blood and bone marrow, including leukemia and lymphoma.

26 Feb 2010

Manhattan Scientifics completes agreement to acquire all commercial rights to Senior Scientific

Manhattan Scientifics Inc., a nanomedicine technology transfer and commercialization pioneer, today announced completion of its agreement to acquire all commercial rights to the body of work of nuclear physicist Edward R. Flynn, PhD and his company, Senior Scientific LLC.

26 Feb 2010

Semafore Pharmaceuticals awarded U.S. patent covering PI-3 kinase inhibitor prodrugs

Semafore Pharmaceuticals today announced today announced the United States Patent and Trademark Office (PTO) has issued United States Patent Number 7,662,977 entitled “PI-3 Kinase Inhibitor Prodrugs.” This composition of matter patent covers a genus of novel compounds that includes SF1126, Semafore’s clinical stage, small molecule inhibitor of phosphoinositide-3-kinase (PI3K) and mammalian target of rapamycin (mTOR), two key members of the PI3K signaling pathway that is vital to several essential biological processes, such as cell proliferation and survival.

25 Feb 2010

Philanthropic organizations fund for cancer research studies

Eight philanthropic organizations and families in the Charlotte region have joined forces to create the "Carolinas Kids Cancer Research Coalition," which is providing funding for the introduction of Phase I and Phase II clinical trials by the Pediatric Hematology and Oncology Center at Levine Children's Hospital (LCH).

25 Feb 2010

EpiCept provides business update and fourth-quarter financial highlights

EpiCept Corporation today announced operating and financial results for the fourth quarter and year ended December 31, 2009, and provided an update on Ceplene® and several of the Company’s key product candidates.

25 Feb 2010

New Barts Cancer Research UK Centre launched

A new cancer centre, launched today, puts London at the forefront of cancer research.

23 Feb 2010

Epicept issues amendment for reduction in company's quorum requirement

EpiCept Corporation announced today that on February 11, 2010, the Board of Directors of EpiCept Corporation adopted an amendment to the company’s Amended and Restated By-Laws to provide that a quorum for the transaction of business at any meeting of the stockholders of the Company shall consist of the holders of one third of the issued and outstanding shares of common stock of the Company.

23 Feb 2010

Cord Blood America announces aim to be world's largest stem cell storage facility

Cord Blood America, Inc., the umbilical cord blood stem cell preservation company focused on bringing the life saving potential of stem cells, a biological insurance policy, for families nationwide and internationally, said today in an interview of Matthew Schissler, co-founder and CEO, by analyst Francis Gaskins, that its goal is to be the world's largest stem cell storage facility.

22 Feb 2010

Leukemia News and Research

Further Reading

Gene 'addiction' of leukaemia cells

Synta Pharmaceuticals receives FDA approval for resuming elesclomol clinical development

Study results of new PCR technology that reports mutations associated with FXS announced

GTC Biotherapeutics achieves high-level production of TG20 monoclonal antibody

ARIAD Pharmaceuticals' investigational pan-BCR-ABL inhibitor receives FDA and EMA orphan drug designation

ChemGenex Pharmaceuticals' OMAPRO review: FDA reschedules ODAC meeting to 22 March, 2010

Aprepitant drug can reduce nausea and vomiting when combined with other anti-nausea drugs

Researchers find gene regulator that plays key role in DS-AMKL

MLL cancer cells rely on normal protein to proliferate

Cancer researchers assess PCI-32765 drug that targets molecular abnormalities of lymphoma cells

Vion Pharmaceuticals' Onrigin SPA: FDA responds

Fate Therapeutics named to Technology Review's 2010 TR50 most innovative companies in the world list

Genoptix to participate in Aetna's national provider network to offer laboratory and diagnostic services

Manhattan Scientifics completes agreement to acquire all commercial rights to Senior Scientific

Semafore Pharmaceuticals awarded U.S. patent covering PI-3 kinase inhibitor prodrugs

Philanthropic organizations fund for cancer research studies

EpiCept provides business update and fourth-quarter financial highlights

New Barts Cancer Research UK Centre launched

Epicept issues amendment for reduction in company's quorum requirement

Cord Blood America announces aim to be world's largest stem cell storage facility

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News